187 related articles for article (PubMed ID: 11240974)
1. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Ishizaki T
Clin Pharmacol Ther; 2001 Mar; 69(3):108-13. PubMed ID: 11240974
[TBL] [Abstract][Full Text] [Related]
2. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
3. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study.
Tanaka M; Yamazaki H; Hakusui H; Nakamichi N; Sekino H
Chirality; 1997; 9(1):17-21. PubMed ID: 9094198
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers.
Tanaka M; Yamazaki H; Ryokawa Y; Hakusui H; Nakamichi N; Sekino H
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):415-9. PubMed ID: 8897077
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of pantoprazole in man.
Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
Int J Clin Pharmacol Ther; 1996 May; 34(5):185-94. PubMed ID: 8738854
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status.
Yasuda S; Horai Y; Tomono Y; Nakai H; Yamato C; Manabe K; Kobayashi K; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1995 Aug; 58(2):143-54. PubMed ID: 7648764
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
9. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.
Bliesath H; Huber R; Hartmann M; Lühmann R; Wurst W
Int J Clin Pharmacol Ther; 1994 Jan; 32(1):44-50. PubMed ID: 8199751
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic differences between pantoprazole enantiomers in rats.
Xie Z; Zhang Y; Xu H; Zhong D
Pharm Res; 2005 Oct; 22(10):1678-84. PubMed ID: 16180125
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats.
Masubuchi N; Yamazaki H; Tanaka M
Chirality; 1998; 10(8):747-53. PubMed ID: 9803530
[TBL] [Abstract][Full Text] [Related]
15. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.
Bliesath H; Huber R; Hartmann M; Lühmann R; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S18-24. PubMed ID: 8793600
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pantoprazole in man.
Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S7-16. PubMed ID: 8793599
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.
Pue MA; Laroche J; Meineke I; de Mey C
Eur J Clin Pharmacol; 1993; 44(6):575-8. PubMed ID: 8405016
[TBL] [Abstract][Full Text] [Related]
18. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S81-5. PubMed ID: 8793608
[TBL] [Abstract][Full Text] [Related]
19. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
20. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers.
Koch HJ; Hartmann M; Bliesath H; Huber R; Steinijans VW; Mascher H; Wurst W
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):420-3. PubMed ID: 8897078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
